Technical Analysis for ASND - Ascendis Pharma A/S
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -1.37% | |
| Lower Bollinger Band Walk | Weakness | -1.37% | |
| Below Lower BB | Weakness | -1.37% |
| Alert | Time |
|---|---|
| Down 2 % | 2 days ago |
| Down 1% | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| 1.5x Volume Pace | 2 days ago |
| Fell Below Previous Day's Low | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 05/02/2024
Ascendis Pharma A/S Description
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Hormones Breakthrough Therapy Pulmonary Arterial Hypertension Peptide Hormones Drug Therapies Growth Hormone Treatment Of Diabetes Growth Hormone Deficiency Recombinant Proteins Growth Hormone Therapy Prodrug Treprostinil
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 161.0 |
| 52 Week Low | 83.75 |
| Average Volume | 348,799 |
| 200-Day Moving Average | 119.18 |
| 50-Day Moving Average | 142.53 |
| 20-Day Moving Average | 134.81 |
| 10-Day Moving Average | 129.53 |
| Average True Range | 5.33 |
| RSI (14) | 25.37 |
| ADX | 35.3 |
| +DI | 7.65 |
| -DI | 36.55 |
| Chandelier Exit (Long, 3 ATRs) | 131.47 |
| Chandelier Exit (Short, 3 ATRs) | 132.60 |
| Upper Bollinger Bands | 148.35 |
| Lower Bollinger Band | 121.26 |
| Percent B (%b) | -0.01 |
| BandWidth | 20.10 |
| MACD Line | -5.46 |
| MACD Signal Line | -4.06 |
| MACD Histogram | -1.4029 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 128.23 | ||||
| Resistance 3 (R3) | 128.65 | 126.71 | 127.05 | ||
| Resistance 2 (R2) | 126.71 | 124.90 | 126.50 | 126.65 | |
| Resistance 1 (R1) | 123.91 | 123.78 | 122.94 | 123.49 | 126.25 |
| Pivot Point | 121.97 | 121.97 | 121.48 | 121.76 | 121.97 |
| Support 1 (S1) | 119.17 | 120.16 | 118.20 | 118.75 | 115.99 |
| Support 2 (S2) | 117.23 | 119.04 | 117.02 | 115.59 | |
| Support 3 (S3) | 114.43 | 117.23 | 115.20 | ||
| Support 4 (S4) | 114.01 |
